AI Proteins

AI Proteins is an early-stage biotech leveraging a proprietary AI-driven platform to design novel miniprotein therapeutics from scratch. The company's closed-loop engine integrates generative AI design, automated synthesis, and lab validation to rapidly create and optimize drug candidates with desired properties like high stability, low immunogenicity, and precise targeting. With a pipeline targeting over 150 drug targets and a significant partnership with Bristol Myers Squibb, AI Proteins is positioning itself at the forefront of next-generation biologic drug discovery.

Closed-loop AI platform for de novo miniprotein design. Integrates generative AI for molecule creation, automated robotics for synthesis, high-throughput lab validation, and an AI-directed mutagenesis engine (AWESSM) for iterative optimization.

AI Proteins competes in the rapidly growing field of AI-driven drug discovery. Direct competitors include companies like Generate Biomedicines, Absci, and Recursion, which also use AI to design novel protein therapeutics, though often with different scaffolds or approaches. It also competes with traditional protein engineering firms and the internal R&D efforts of large biopharma companies investing heavily in computational biology.